However, despite animal models consistently showing increased brain acetylcholine and improved cognitive deficits in AD, the clinical effectiveness of AChE inhibitors, including natural alkaloids huperzine A and galantamine, remains a subject of debate due to challenges related to bioavailability and various side effects [3,4,5]. The gene discussed is ACHE; the disease is Alzheimer disease.